CNS-1261 (PAION)

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameCNS-1261 (PAION)
Drug Alias NameCNS-1261
ClassificationDiagnostic agent (In vivo)Small molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPaion Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsSchizophrenia

Other Information

ATC CodeN/A
Related LinksN/A